Bardin Stephen 4

What Happened

• Stephen Bardin, Chief Financial Officer of CalciMedica, was granted 67,728 shares (reported as a derivative award) on 2025-04-05 at an acquisition price of $0.00. The award was reported on a Form 4 filed 2026-04-07.
• The grant carries a vesting schedule that begins April 1, 2026: 1/48th of the shares vest each month over four years. However, no shares will vest until the company files a Form S‑8 registering the shares that were added to the 2023 Equity Incentive Plan on January 1, 2026.

Key Details

• Transaction date: 2025-04-05; Form 4 filed: 2026-04-07.
• Transaction type/code: A (award/grant); Price reported: $0.00; Shares granted: 67,728 (derivative).
• Vesting: 1/48th per month starting 2026-04-01, but contingent on filing a Form S‑8 (per footnote).
• Shares owned after transaction: Not disclosed in the filing.
• Timeliness: The filing date (2026-04-07) reports a grant dated 2025-04-05; SEC rules typically require Form 4 within two business days of the transaction. The filing does not explain the gap.

Context

• This was an equity award (not a market purchase or sale). Because it vests over time and is contingent on a registration statement, it’s meant to align the executive’s incentives with long-term performance rather than provide immediate liquidity.
• For retail investors: awards indicate future potential insider ownership if vesting conditions are met, but they do not necessarily imply immediate buying or selling intent.